Genmab Holding B.v.

Genmab B.v.

Genmab A+s

Marije Overdijk

Paul Parren

Esther Breij

Frank Beurskens

Edward Norbert Van Den Brink

Margaret A Lindorfer

Simone Oostindie

Tuna Mutis

Martine E D Chamuleau

Hilma Van Der Horst

Andreas Hollenstein

Janine Schuurman

Ronald P Taylor

Kristin Strumane

David Satijn

Rik Rademaker

Rob N De Jong

Patrick Van Berkel

Sandra Verploegen

Willem Karel Bleeker

Steen Lisby

Ilse Jongerius

Ronald Taylor

Theodorus Sjouke Plantinga

Madelon Paauwe

Jamila Laoukili

Onno Wouter Kranenburg

Bart Ecg De Goeij

Grietje Andringa

Annieck M Diks

Riemke Van Dijkhuizen

CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.

Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof

The present invention relates to a multispecific antibody comprising at least a FAPα binding region comprising a first heavy chain variable region and a first light chain variable region; and a DR4 binding region comprising a second heavy chain variable region and a second light chain variable region. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

Antibodies binding to fibroblast activation protein alpha and death receptor 4

The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signalling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.

Anti-DR5 antibodies and methods of use thereof

As described herein are polypeptides and antibodies having an Fc region and an antigen binding region where the Fc region has an Fc-Fc-enhancing mutation and a C1q binding-enhancing mutation providing for polypeptides or antibodies with increased CDC activity and/or agonistic activity.

Polypeptide variants and uses thereof

The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signaling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.

Isolated human monoclonal antibodies which bind to human CD74 and related antibody-drug conjugates are disclosed. Pharmaceutical compositions comprising the antibodies or antibody-drug conjugates, and therapeutic and diagnostic methods for using the antibodies and/or antibody-drug conjugates, are also disclosed.

Human antibodies and antibody-drug conjugates against CD74

Growing community of inventors

Utrecht, Netherlands

Marije Overdijk